# Pharmacokinetics of Salmeterol (Serevent®) After Inhalation With Metered Dose Inhaler (MDI) and Diskus® in Healthy Male Volunteers

> **NCT02254226** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 26 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Salmeterol Diskus low
- **DRUG:** Salmeterol Diskus high
- **DRUG:** Salmeterol MDI low
- **DRUG:** Salmeterol MDI high

## Key facts

- **NCT ID:** NCT02254226
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2005-01
- **Final completion:** —
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2014-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02254226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02254226, "Pharmacokinetics of Salmeterol (Serevent®) After Inhalation With Metered Dose Inhaler (MDI) and Diskus® in Healthy Male Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02254226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*